ChartRow logo
Data provided bySource: Twelve Data
RVTY
$155.11+2.84%
as of close, Nov 6, 2026
☾ AH $155.11 +2.84%
PeersWATDHRCRLMEDPICLRILMN
Share this page

RVTY — Revvity Inc. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in RVTY be worth today? →
RVTY returns: By year · By month · By week · Trailing

Price data

Price
$155.11
YTD price return
+60.32%
YTD total return
+60.72%
Market cap
17.3B
Enterprise value
19.7B
Shares outstanding
111.6M
52W low
$81.22
52W high
$171.74
From 52W high
-9.68%
From 52W low
+90.98%
52W range
82%$81.22–$172
Beta
1.07

Volume

Rel volume
0.86×
30D volume
2M
30D $ vol
304.7M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$1.3M
Insider net 1Y
−$6.0M

Form 4 transactions by trade date, as filed; latest on file 2026-10-01.

Fundamentals

Sales (ttm)
2.9B
Sales/share
$26.09
EPS (ttm)
$2.10
FCF (ttm)
558.1M
FCF/share
$5.00
Book value/share
$64.78
Net margin
8.16%
ROE
3.29%
ROA
1.97%
Debt / equity
0.36×
Current ratio
1.80

Growth (CAGR, ttm) · 10Y

Sales
+3.99%+0.87%-9.71%+3.12%
Net income
-16.47%-33.70%-27.45%+0.13%
FCF
+10.79%+53.67%-16.55%+7.20%
Shares
-3.81%-3.48%-0.09%+0.20%

Per-share growth (CAGR, ttm) · 10Y

EPS
-11.03%-31.15%-27.52%+0.01%
Sales/share
+8.10%+4.51%-9.63%+2.93%
FCF/share
+15.17%+59.21%-16.47%+6.99%
Book value/share
-0.48%+0.72%+11.36%+12.99%
Dividend/share
+0.00%-0.53%+0.00%+0.00%
Price
+73.33%+21.94%-1.68%+11.74%
Total return
+73.76%+22.26%-1.44%+12.06%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
73.8×
P/OI (ttm)
48.2×
Fwd P/E
25.4×
P/S (ttm)
5.9×
P/B (mrq)
2.4×
P/FCF (ttm)
31.0×
EV/EBITDA (fy)
25.5×
EV/Sales (ttm)
6.8×
FCF yield (ttm)
3.22%
Dividend yield (fwd)Div yield
0.18%
Dividend yield (ttm)
0.18%
Dividend/share (fwd)
$0.28
Buyback yield (realized, 1y)
3.81%
Shareholder yield (realized, 1y)
4.08%
Buyback yield (cash, ttm)
2.75%
Shareholder yield (cash, ttm)
2.93%

Vs own 10Y history

P/E
92nd
P/OI
95th
P/S
97th
P/B
40th
P/FCF
63rd

Bar = where today’s multiple sits in RVTY’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data
1D
+2.84%
5D
-1.20%
1M
+1.18%
3M
+35.78%
YTD
+60.32%
1Y
+73.27%
5Y
-8.13%
1D
+2.84%
5D
-1.20%
1M
+1.23%
3M
+35.84%
YTD
+60.72%
1Y
+73.70%
5Y
-7.02%

Fundamentals#

Revenue

5Y CAGR +1.4%10Y CAGR +3.1%YoY +1.3%
$2.9B TTM$729.7M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Operating income

5Y CAGR −16.3%10Y CAGR +3.6%YoY −1.6%
$358.8M TTM$89.3M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

EPS (diluted)

5Y CAGR −20.4%10Y CAGR +1.0%YoY +2.2%
$2.10 TTM$0.47 Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Free cash flow

5Y CAGR −9.3%10Y CAGR +7.0%YoY +56.7%
$558.1M TTM$180.9M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $627.6M, capex −$69.5M

Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Q2 2026: operating cash flow $191.9M, capex −$11.1M

Shares (diluted)

5Y +4.0%10Y +2.9%YoY −5.0%
113M TTM111.6M Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Dividend per share

5Y CAGR +0.0%10Y CAGR +0.0%YoY +0.0%
$0.28 TTM$0.07 Q2 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '16Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Full RVTY financials →

Revvity Inc. is a global life sciences and diagnostics company that provides health science solutions, technologies, and services for research, development, and clinical testing. Revvity’s current business is organized around two main segments: Life Sciences, which supplies reagents, instruments, and software to support biopharma and academic research; and Diagnostics, which offers assay platforms, instruments, and software for reproductive health, immunodiagnostics, newborn screening, applied genomics, and infectious disease testing. The company also focuses on translational multi-omics, biomarker identification, imaging, screening, detection, and informatics, helping customers move biological data through connected laboratory workflows. Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across global markets. Headquartered in Waltham, Massachusetts, Revvity plays an important role in enabling scientific discovery and supporting clinical decision-making across the healthcare and research ecosystem.

Waltham, MA·11,000 employees·Diagnostics & Research·revvity.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding RVTY#

27 of the 193 ETFs ChartRow carries live hold RVTY. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VBRVanguard Small-Cap Value ETF0.3%
XLVHealth Care Select Sector SPDR Fund0.2%
RSPInvesco S&P 500 Equal Weight ETF0.2%
VHTVanguard Health Care ETF0.2%
VBVanguard Small-Cap ETF0.2%
IWSiShares Russell Mid-Cap Value ETF0.1%
IWRiShares Russell Midcap ETF0.1%
SPYVSPDR Portfolio S&P 500 Value ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.42%+1.43%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.14%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.74%-0.40%
NVSNovartis AG+15.46%+0.38%
TMOThermo Fisher Scientific Inc.+5.81%+2.63%
AMGNAmgen Inc.+14.36%+0.03%